

FACTORIAL STUDIES ON ENHANCEMENT OF DISSOLUTION RATE AND FORMULATION OF ACECLOFENAC TABLETS EMPLOYING β CD AND KOLLIPHOR HS15

S. GOPINATH¹, C. UMAMAHESWARA REDDY¹, K. P. R. CHOWDARY*²

¹Faculty of Pharmacy, Sri Ramachandra University, Porur, Chennai 600116. T. N., ²A. U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam 530003, A. P.
Email: prof.kprchowdary@rediffmail.com

Received: 19 Nov 2014, Revised and Accepted: 24 Dec 2014

ABSTRACT

Aceclofenac is an effective anti-inflammatory and analgesic drug. It belongs to class II under Biopharmaceutical classification system and exhibit low and variable oral bioavailability due to its poor solubility. It is practically insoluble in water and aqueous fluids and its oral absorption is dissolution rate limited. It needs enhancement in solubility and dissolution rate for improvement of its oral bioavailability and therapeutic efficacy. The objective of the present study is to enhance the dissolution rate and formulation development of aceclofenac tablets with fast dissolution characteristics employing β CD and Kolliphor HS15, a non ionic surfactant. The individual and combined effects of β CD (factor A) and Kolliphor HS15 (factor B) on the dissolution rate of aceclofenac from solid inclusion complexes and their tablets were evaluated in a series of 2² factorial experiments. The feasibility of formulating aceclofenac - β CD-Kolliphor HS15 inclusion complexes into tablets with fast dissolution rate characteristics was also investigated. Kolliphor HS15 has not been investigated earlier for this purpose.

The individual and combined effects of β CD and Kolliphor HS15 in enhancing the dissolution rate and dissolution efficiency of aceclofenac from solid inclusion complexes and their tablets were highly significant ($P < 0.01$). The dissolution of aceclofenac was rapid and higher in the case of aceclofenac- β CD and aceclofenac- β CD - Kolliphor HS15 complexes prepared when compared to aceclofenac pure drug. β CD alone gave a 8.66 fold increase and in combination with Kolliphor HS15 it gave 9.85 fold increase in the dissolution rate of (K_1) of aceclofenac. Aceclofenac - β CD - Kolliphor HS15 inclusion complexes could be formulated into compressed tablets by wet granulation method and the resulting tablets also gave rapid and higher dissolution of aceclofenac. Aceclofenac tablets formulated with β CD and Kolliphor HS15 individually gave 4.75 and 6.1 fold increase in the dissolution rate and those containing drug - β CD -Kolliphor HS15 complex gave much higher enhancement (21.35 fold) in the dissolution rate when compared to tablets formulated with aceclofenac pure drug. Combination of β CD and Kolliphor HS15 gave much higher enhancement in the dissolution rate of aceclofenac tablets than is possible with them individually. A combination of β CD with Kolliphor HS15 is recommended to enhance the dissolution rate in the formulation development of aceclofenac tablets with fast dissolution rate characteristics.

Keywords: Aceclofenac, β Cyclodextrin, Kolliphor HS15, Dissolution Rate, Aceclofenac Tablets, Formulation development.

INTRODUCTION

Aceclofenac is an effective anti-inflammatory and analgesic drug. It belongs to class II under Biopharmaceutical classification system and exhibit low and variable oral bioavailability due to its solubility. It is practically insoluble in water and aqueous fluids and its oral absorption is dissolution rate limited. It needs enhancement in solubility and dissolution rate for improvement of its oral bioavailability and therapeutic efficacy. Techniques used to enhance the solubility, dissolution rate and bioavailability of poorly soluble drugs are reported¹ in detail. Complexation [2-5] with β cyclodextrin (β CD) and use of surfactants [6-8] are two industrially used techniques in the formulation development of insoluble drugs to enhance their solubility and dissolution rate.

The objective of the present study is enhancement of dissolution rate and formulation of aceclofenac tablets with fast dissolution characteristics employing β CD and Kolliphor HS15, a non ionic surfactant. Kolliphor HS15 is reported as non toxic and safe for human and animal use⁹. The study was conducted as a 2² factorial experiment. The individual and combined effects of β CD (factor A) and Kolliphor HS15 (factor B) on the dissolution rate of aceclofenac from solid inclusion complexes and their tablets were evaluated in a series of 2² factorial experiments. The feasibility of formulating aceclofenac - β CD-Kolliphor HS15 inclusion complexes into tablets with fast dissolution rate characteristics was also investigated. Kolliphor HS15 has not been investigated earlier for this purpose.

MATERIALS AND METHODS

Materials

Aceclofenac was obtained from Ms/ Hetero Drugs Ltd., Hyderabad. β -cyclodextrin, Kolliphor HS15, Croscarmellose Sodium, Lactose and

PVP K30 were procured from commercial sources. All other materials used were of Pharmacopoeial grade.

Methods

Estimation of aceclofenac

Aceclofenac was estimated by UV spectrophotometric method and absorbance was measured at 275 nm using phosphate buffer of pH 6.8 as solvent. Validation of the method was carried out for accuracy, precision, interference and linearity. The method exhibited linearity in the concentration range 0-10 μ g/ml. The accuracy (relative error) and precision (RSD) of the method were found to be 0.65% and 1.45 % respectively. It was observed that the excipients used did not have any interference in the method of analysis.

Preparation of aceclofenac - β CD Complexes

Solid inclusion complexes of Aceclofenac - β CD - Kolliphor HS15 were prepared by kneading method. Aceclofenac, β CD and Kolliphor HS15 were triturated in a dry mortar with a small volume of solvent dichloromethane. The thick slurry formed was kneaded for 45 min and then dried at 55°C until it becomes dry. The dried mass was powdered and screened through sieve No.120.

Preparation of aceclofenac tablets employing β CD complexes

Aceclofenac (100 mg) tablets were prepared as per 2² - factorial study by wet granulation method employing aceclofenac- β CD - Kolliphor HS15 inclusion complexes as per the formulae given in table 1. Drug-CD-Kolliphor HS15 complex systems were initially prepared in each case by kneading method. To the dried complex in the mortar lactose and PVP were added and mixed thoroughly. Water (q. s) was added and mixed thoroughly to form a dough mass. The mass was pressed through mesh No. 12 to obtain wet granules.

After drying the wet granules at 60°C for 4 hr, they were passed through mesh No. 16 to break the aggregates. To this dried granules croscarmellose sodium, talc and magnesium stearate (already screened through sieve No.100) were added and mixed thoroughly in a polyethylene bag. Then the granules were punched into tablets using a 16 station tablet punching machine (M/s. Rimek) using 9 mm flat and round punches.

Evaluation of tablets

All the prepared tablets were evaluated for drug content, hardness, friability, disintegration time and dissolution rate. Monsanto hardness tester was used for testing hardness of the tablets prepared.

Friability of the tablets was determined in a Roche friabilator. Disintegration time of the tablets was tested in a Thermonic tablet disintegration test machine using water as test fluid.

Dissolution rate study

Acetoclofenac dissolution from β CD - Kolliphor HS15 inclusion complexes and their tablets was studied in phosphate buffer of pH 6.8 (900 ml) using Electro Lab 8 station dissolution rate test apparatuses.

A paddle stirrer at 50 rpm and a temperature of 37 \pm 1°C was used. Inclusion complex or tablet containing 100 mg of acetoclofenac was used in each test.

Table 1: Formulae of acetoclofenac tablets prepared employing β CD and kolliphor HS15 as per 2²factorial design

Ingredient (mg/tab)	Formulation			
	F ₁	F _a	F _b	F _{ab}
Acetoclofenac	100	100	100	100
β -CD	--	200	--	200
Kolliphor HS15	--	--	5	5
Croscarmellose Sodium	15	15	15	15
PVP K30	7	7	7	7
Talc	7	7	7	7
Magnesium stearate	7	7	7	7
Lactose	214	14	209	9
Total weight (mg)	350	350	350	350

Table 2: Dissolution parameters of acetoclofenac- β CD-kolliphor HS15 inclusion complexes prepared as per 2² factorial study

Ace-CD complex (Statistical Code as per 2 ² Factorial design)	DE ₁₅ (%)		K ₁ \times 10 ² (min ⁻¹)	
	\bar{X}	Increase (no. of folds)	\bar{X}	Increase (no. of folds)
Acetoclofenac (1)	10.11	-	5.27	-
Acetoclofenac- β CD (a)	63.87	6.31	45.66	8.66
Acetoclofenac -Kolliphor HS15 (b)	52.17	5.16	40.85	7.75
Acetoclofenac - β CD- Kolliphor HS15 (ab)	73.89	7.30	51.90	9.85

Table 3: ANOVA of K₁ \times 10² (min⁻¹) values of acetoclofenac complexes formulated employing β CD and kolliphor HS15as per 2²factorial design

Source of Variation	d. f.	S. S	M. S. S	F-Ratio	Significance
Total	15	10101.32	673.42	--	--
Treatments	3	9346.76	3115.58	49.54	P< 0.01
a (β CD)	1	5697.23	5697.23	90.6	P< 0.01
b (Kolliphor HS15)	1	2712.32	2712.32	43.13	P< 0.01
ab (combination)	1	1027.2	1027.2	16.33	P< 0.01
Error	12	754.56	62.88	--	--

$$F_{0.01(1,12)}=9.33; F_{0.01(3,12)}=5.95$$

Table 4: Hardness, friability, disintegration time and drug content of acetoclofenac tablets formulated employing β CD and kolliphor HS15

Formulation (code as per 2 ² -Factorial Design)	Hardness (kg/sq. cm)	Friability (%)	Disintegration Time (min.)	Acetoclofenac content (mg/tablet)
F ₁	7.0	0.54	3.5	99.4
F _a	6.5	0.64	2.5	98.2
F _b	6.0	0.35	2.0	100.6
F _{ab}	7.5	0.65	2.0	98.8

Table 5: Dissolution parameters of acetoclofenac tablets formulated employing β CD-kolliphor hs15as per 2²factorial design

Formulation	DE ₃₀ (%)		K ₁ (min ⁻¹) \times 10 ²	
	\bar{X}	Increase in DE ₃₀ (NO. of folds)	$\bar{X} \pm$ s. d.)	Increase in K ₁ (NO. of folds)
F ₁	7.29	-	0.2 \pm 0.01	-
F _a	22.11	3.03	0.95 \pm 0.057	4.75
F _b	31.77	4.35	1.22 \pm 0.057	6.1
F _{ab}	43.32	5.94	4.27 \pm 0.40	21.35

Table 6: ANOVA of $K_1 \times 10^2$ (min^{-1}) values of Aceclofenac Tablets Formulated Employing β CD and Kolliphor HS15as per 2^2 Factorial Design

Source of Variation	d. f.	S. S	M. S S	F-Ratio	Significance
Total	15	39.28	2.61	--	--
Treatments	3	38.65	12.88	247.69	$P < 0.01$
a (β -CD)	1	14.44	14.44	277.69	$P < 0.01$
b (Kolliphor HS15)	1	18.92	18.92	363.84	$P < 0.01$
ab (combination)	1	5.29	5.29	101.73	$P < 0.01$
Error	12	0.63	0.052	--	--

$$F_{0.01(1,12)}=9.33; F_{0.01(3,12)}=5.95$$

Samples of dissolution media (5 ml) were withdrawn through a filter (0.45μ) at 5, 10, 20, 30, 40, 50 and 60 min, suitably diluted and assayed for aceclofenac at 275 nm. The sample of dissolution fluid withdrawn at each time was replaced with fresh fluid. The dissolution experiments were replicated three times each ($n=3$).

Analysis of results

Dissolution data were analysed as per zero order and first order kinetics to evaluate the dissolution rates. Dissolution efficiency (DE_{15}) values were calculated as per the method of Khan[10]. Dissolution data were also analyzed by Analysis of Variance (ANOVA) of 2^2 factorial studies.




Fig. 1: Dissolution profiles of aceclofenac- β CD- kolliphor HS15 complex systems formulated as Per 2^2 factorial design




Fig. 2: Dissolution profiles of aceclofenac tablets formulated employing β CD and kolliphor HS15as per 2^2 factorial design

RESULTS AND DISCUSSION

The objective of the present study is to enhance the dissolution rate and formulation of aceclofenac tablets with fast dissolution characteristics employing β CD and Kolliphor HS15, a non ionic surfactant. The individual and combined effects of β CD (factor A) and Kolliphor HS15 (factor B) on the dissolution rate of aceclofenac from solid inclusion complexes and their tablets were evaluated in a series of 2^2 factorial experiments. The feasibility of formulating aceclofenac - β CD-Kolliphor HS15 inclusion complexes into tablets with fast dissolution rate characteristics was also investigated. Kolliphor HS15 has not been investigated earlier for this purpose.

For 2^2 factorial experiments on dissolution rate, the two levels of β CD (factor A) are 0 and 1:2 ratio of drug: β CD and the two levels of Kolliphor HS15 (factor B) are 0 and 2 %. Accordingly the four treatments involved are aceclofenac pure drug (1), aceclofenac- β CD (1:2) inclusion complex (a), aceclofenac - Kolliphor HS15 (2%) complex (b) and aceclofenac- β CD (1:2) - Kolliphor HS15 (2%) complex (ab). The complexes were prepared by kneading method.

The prepared solid inclusion complexes were fine and free flowing powders. Low RSD values < 1.4 % in the percent drug content indicated uniformity of drug content in each batch of solid inclusion complexes prepared.

The dissolution rate of aceclofenac from the β CD complexes prepared was studied in phosphate buffer of pH 6.8. The dissolution profiles are shown in Fig.1. The dissolution of aceclofenac followed first order kinetics with R^2 (coefficient of determination) values greater than 0.9254. The dissolution parameters estimated are given in Table-2. All the dissolution parameters indicated rapid and higher dissolution of aceclofenac from the aceclofenac- β CD and aceclofenac- β CD - Kolliphor HS15 complexes when compared to aceclofenac pure drug.

The results of ANOVA (Table 3) indicated that the individual main effects of β CD and Kolliphor HS15 and their combined effects in enhancing the dissolution rate (K_1) and dissolution efficiency (DE_{15}) were highly significant ($P < 0.01$). β CD individually gave a 8.66 fold increase in the dissolution rate of (K_1) of aceclofenac. Whereas when it is combined with Kolliphor HS15 the dissolution rate (K_1) was enhanced by 9.85 fold. Kolliphor HS15 (F_b) individually also gave 7.75 fold increase in the dissolution rate (K_1) of aceclofenac. DE_{15} values were also much higher in the case of β CD - Kolliphor HS15 solid complexes when compared to aceclofenac pure drug.

The aceclofenac - β CD - Kolliphor HS15 solid complexes (1,a,b,ab) were formulated into tablets by wet granulation method as per the formulae given in table 1. All the prepared tablets were tested for drug content, hardness, friability and disintegration time and dissolution rate of aceclofenac. The results are given in Tables 4-5 and Fig. 2. Aceclofenac content of the tablets was within $100 \pm 2\%$ of the labeled claim. Hardness of the tablets was in the range 6.0-7.5 Kg / cm^2 . Percentage weight loss was less than 0.65% in the friability test. All the tablets formulated employing inclusion complexes disintegrated rapidly within 3.5 min.

Dissolution of aceclofenac from all the tablets prepared followed first order kinetics with the coefficient of determination (R^2) values greater 0.925. Aceclofenac dissolution was rapid and higher from the tablets formulated employing drug- β CD- Kolliphor HS15 inclusion complexes when compared to the tablets containing aceclofenac pure drug. The results of ANOVA (Table 6) indicated that the individual as well as combined effects of the two factors involved i. e., β CD (factor A) and Kolliphor HS15 (factor B) were highly significant ($P < 0.01$) in enhancing the dissolution rate (K_1) and dissolution efficiency (DE_{15}) of aceclofenac tablets.

Tablets F_a and F_b formulated respectively with β CD and Kolliphor HS15 alone gave 4.75 and 6.1 fold increase in the dissolution rate when compared to control tablets F_1 formulated with aceclofenac pure drug. Tablets F_{ab} containing drug - β CD -Kolliphor HS15 complex gave much higher enhancement (21.35fold) in the dissolution rate when compared to control formulation F_1 and also

formulations F_a and F_b . Thus combination of β CD and Kolliphor resulted in a much higher enhancement in the dissolution rate of aceclofenac tablets than is possible with them individually.

Based on the results obtained, a combination of β CD with Kolliphor HS15 is recommended to enhance the dissolution rate in the formulation development of aceclofenac tablets with fast dissolution rare characteristics.

CONCLUSION

1. The individual and combined effects of β CD and Kolliphor HS15 in enhancing the dissolution rate and dissolution efficiency of aceclofenac from solid inclusion complexes and their tablets were highly significant ($P < 0.01$).

2. The dissolution of aceclofenac was rapid and higher in the case of aceclofenac- β CD and aceclofenac- β CD - Kolliphor HS15 complexes prepared when compared to aceclofenac pure drug. β CD alone gave a 8.66 fold increase and in combination with Kolliphor HS15 it gave 9.85 fold increase in the dissolution rate of (K_1) of aceclofenac.

3. Aceclofenac - β CD - Kolliphor HS15 inclusion complexes could be formulated into compressed tablets by wet granulation method and the resulting tablets also gave rapid and higher dissolution of aceclofenac.

4. Aceclofenac tablets formulated with β CD and Kolliphor HS15 individually gave 4.75 and 6.1 fold increase in the dissolution rate and those containing drug - β CD -Kolliphor HS15 complex gave much higher enhancement (21.35 fold) in the dissolution rate when compared to tablets formulated with aceclofenac pure drug. Combination of β CD and Kolliphor HS15 gave much higher enhancement in the dissolution rate of aceclofenac tablets than is possible with them individually.

HS15

5. A combination of β CD with Kolliphor HS15 is recommended to enhance the dissolution rate in the formulation development of aceclofenac tablets with fast dissolution rate characteristics.

REFERENCES

1. Chowdary KPR, Madhavi BLR. Novel drug delivery technologies for insoluble drugs. *Indian Drugs* 2005;42(9):557-62.
2. Fromming KH, Szejtli J. *Cyclodextrins in Pharmacy*. Kluwer Academic Publications, Dordrecghi; 1994. p. 20.
3. Duchene D, Woussidjewe D, Dumitriu S. *Polysaccharides in Medical Applications*. Marcel Dekker: New York; 1996. p. 575-602.
4. Thompson DO. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. *Crit Rev Therapeutic Drug Carrier System* 1997;14(1):1-104.
5. Hedges AR. Industrial applications of cyclodextrins. *Chem Rev* 1998;98:2035-44.
6. Rajebahadur M, Zia H, Nues A, Lee C. Mechanistic study of solubility enhancement of nifedipine using vitamin E TPGS or solutol HS-15. *Drug Delivery* 2008;13(3):201-6.
7. Alani, AW, Rao DA, Seidel R, Wang J, Jiao J, Kwon GS. The effect of novel surfactants and Solutol HS 15 on paclitaxel aqueous solubility and permeability across a Caco-2 monolayer. *J Pharm Sci* 2010;99(8):3473-85.
8. Han HK, Lee BJ, Lee HK. Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation. *Int J Pharm* 2011;30(1-2):89-94.
9. Sherry KU, Ranga Velageti. *Pharmaceutical Technology*; 2010. p. 108-10.
10. Khan KA. The concept of dissolution efficiency. *J Pharm Pharmacol* 1975;27:48-9.